Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1434868/000110465919037687/a19-12141_18k.htm
August 2023
June 2023
June 2023
May 2023
May 2023
March 2023
March 2023
March 2023
March 2023
March 2023
Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1434868/000110465919037687/a19-12141_18k.htm
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Esperion Therapeutics, Inc..
Esperion Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:
Material Contracts, Statements, Certifications & more
Esperion Therapeutics, Inc. provided additional information to their SEC Filing as exhibits
Ticker: ESPREvents:
CIK: 1434868
Form Type: 8-K Corporate News
Accession Number: 0001104659-19-037687
Submitted to the SEC: Wed Jun 26 2019 5:18:23 PM EST
Accepted by the SEC: Wed Jun 26 2019
Period: Wednesday, June 26, 2019
Industry: Pharmaceutical Preparations